Incyte Corporation, based in Delaware, focuses on developing therapies for various medical challenges with a market cap of around $19.6 billion. Their stock has surged 49% over the past year, outperforming the S&P 500 Index. Despite a revenue growth exceeding expectations, their adjusted EPS fell short, leading to an 8.2% drop in shares. The company remains optimistic about future launches and regulatory approvals, with analysts forecasting a 19.4% growth in diluted EPS for fiscal 2026. Analysts have an overall “Moderate Buy” rating for INCY stock, with price targets indicating potential upside.

Read more at Barchart: Do Wall Street Analysts Like Incyte Corporation Stock?